论文部分内容阅读
目的：探讨核苷类抗病毒药物疗法在乙肝肝硬化患者治疗中的应用价值。方法将94例乙肝肝硬化患者随机分组，治疗组（n=47）在常规治疗基础上加用核苷类抗病毒药物疗法，对照组（n=47）应用常规疗法，对比2组疗效。结果①治疗组患者不良反应发生率是6.38%，低于对照组患者的19.15%（P＜0.05）；②治疗组乙肝病毒DNA转阴率是93.62%，显著高于对照组的6.38%（P＜0.01）；③治疗组患者AST、ALT、TBiL水平均低于对照组（均P＜0.01），而ChE水平则高于对照组（P＜0.01）。结论核苷类抗病毒药物疗法在乙肝肝硬化患者治疗中的应用价值显著，可借鉴。“,”Objective To investigate the antiviral nucleoside therapy applications in the treatment of patients with liver cirrhosis. Methods 94 cases of liver cirrhosis patients randomized to the treatment group (n= 47) in the conventional treatment based on the use of nucleoside antiviral therapy, the control group (n=47) with conventional therapy, compared to the efficacy of the two groups. Results ① incidence of complications in the treatment group was 6.38%, lower than the 19.15%of patients in the control group (P<0.05);②treatment group HBV DNA negative rate was 93.62%, significantly higher than the 6.38% (P<0.01);AST patients③treatment group, ALT, TBiL levels were lower than the control group (P<0.01), and ChE levels were higher than (P<0.01). Conclusion Nucleoside antiviral therapy applications in the treatment of patients with liver significantly, can learn.